Werewolf Therapeutics (HOWL)
(Delayed Data from NSDQ)
$6.07 USD
-0.01 (-0.16%)
Updated May 3, 2024 04:00 PM ET
After-Market: $6.05 -0.02 (-0.33%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Werewolf Therapeutics, Inc. [HOWL]
Reports for Purchase
Showing records 21 - 40 ( 41 total )
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
INDUKINEs Take a Step Closer In Transforming Cancer Therapy; Reit Buy and $20PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Green Light for WTX-124 IND Begins Assault on Solid Tumors; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Reflections of ASCO 22 - Part One: Cytokine Modalities Continue to Remain Overlooked
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Assuming Coverage With a Buy Rating and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q 2021 results; IND Filing for Engineered IL-2 Candidate WTX-124 Set for 2Q 2022; 2nd IND for WTX-330 Set for 3Q 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bempeg Disappoints With Phase 3 Failure; Remain Optimistic on WTX-124 Based on Differentiated Profile
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Data From Twin Posters at AACR Supports Clinical Development of Engineered Cytokine Candidates WTX-124 and WTX-330
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Deep Dive on Engineered Cytokines; Using Modern Technology to Teach Old Dogs New Tricks
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Werewolf Presents Preclinical Data Demonstrating Anti- Tumor Activity of INDUKINES in Hematological Malignancies
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Poster Presentation at ASH Set to Include First Demonstration of INDUKINE Anti-Tumor Activity in Mouse Lymphoma Model
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Werewolf Presents Platform Validating Preclinical Data at SITC
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Werewolf Reports 3Q21; IND Filing Plans on Track for 1H 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Paper in Science Immunology Suggests Cytokine Priming is Key to Overcoming Resistance to Immune Checkpoint Blockade
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from Fireside Chat with Engineered Cytokine Wunderkind Werewolf Therapeutics
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Werewolf Announces Deal With Merck to Test IL-2 INDUKINE - Keytruda Combo in Solid Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HOWL Reports 2Q21; Reiterate Buy and Maintain PT at $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HOWL Reports 1Q21; Updating Model; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Engineered Cytokines Drawing a Crowd, in a Good Way
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Modified IL-2 Constructs from Competitors Gain Attention at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department